PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL
New Leukemia Treatment Keeps Adult Patient Cancer Free For Seven Years
This retrospective observational analysis of a single clinical case describes an adult patient with early-relapsed, chemorefractory B-cell a…
A new dual-targeted therapy helped an adult with tough leukemia stay cancer-free for seven years after standard treatments failed.
Review of pediatric B-ALL CAR-T therapy identifies RAS mutation outcome predictor
New Test Predicts CAR-T Success in Kids
This narrative review synthesizes observational data from 86 pediatric patients with relapsed or refractory B-cell acute lymphoblastic leuke…
A new test can spot hidden genetic risks before a child starts powerful CAR-T cancer therapy.